Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary

Journal of Oncology
Aman ChauhanLowell Anthony

Abstract

Incidence of low grade well-differentiated neuroendocrine tumors (NET) is on the rise. The North American Neuroendocrine Tumor Society estimates that the United States has more than 150,000 gastroenteropancreatic NET patients. About 10% of metastatic NETs can be unknown primary, and due to their rarity, dedicated treatment algorithms and regimens are not defined. Combination of capecitabine and temozolomide (CAPTEM) is one of the systemic treatments used in gastroenteropancreatic NETs. We explored clinical activity of CAPTEM in NET of unknown primary. Methods. Retrospective review of NET of unknown primary managed at the University of Kentucky over the past five years (2012-2016). Result. 56 patients with NET of unknown primary were identified; 12 patients were treated with CAPTEM. Median progression-free survival on CAPTEM in grade II and grade III NET of unknown primary was 10.8 and 7 months, respectively. Six patients showed reduction in metastatic tumor volume at three-month CT scan. Three patients had stable disease and three patients showed disease progression at the first surveillance scan. Common side-effects were as follows: four patients developed grade II thrombocytopenia, three patients developed grade I lymphocytop...Continue Reading

References

Dec 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria A KouvarakiJames C Yao
Feb 15, 2005·The Oncologist·Johanna M Zuetenhorst, Babs G Taal
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew H KulkeMark S Redston
May 27, 2016·The Oncologist·Robert A RamirezEugene A Woltering

❮ Previous
Next ❯

Software Mentioned

CAPTEM

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.